Write a review
Reviews: 0
Manufacturers: Aventis Pharma (UK)
Active ingredients
- Nedocromil sodium
Disease class
- Asthma
Clinical and pharmacological group
- Not indicated. See instructions
Pharmacological action
- Anti-inflammatory
- Antiallergic
Pharmacological group
- Mast cell membrane stabilizers
Release form and composition
The dosage form of Tiled Minta is a dosed aerosol for inhalation: the contents of the aluminum canister after evaporation of the propellant are yellow powder (112 doses in aluminum aerosol canisters with a dosing device, 1 canister in a cardboard box, complete with or without a synchronizer).
Composition of 1 dose:
- active substance: nedocromil sodium – 2 mg;
- auxiliary components: polyethylene glycol (macrogol) 600 - 0.426 mg, povidone K30 - 0.035 5 mg, propellant HFA-227 - up to 142 mg, levomenthol - 0.071 mg.
Drug interactions
Nedocromil sodium is compatible with many medications, including GCS (glucocorticosteroids), β-adrenergic stimulants, ipratropium bromide, theophylline and other methylxanthines.
When bronchodilators are prescribed simultaneously, it is recommended to use them before inhalation of nedocromil sodium. In patients receiving GCS, when adding Tailed Mint to therapy, it is possible to reduce the maintenance dose of GCS or completely discontinue it. The dose of GCS is reduced gradually, by about 10% weekly, and strict monitoring of the patient is required. If it is impossible to reduce the dose of GCS, nedocromil sodium should not be discontinued until GCS cover is restored.
Directions for use and dosage
Tailed Mint is intended for regular daily use. The drug is not used to relieve acute bronchospastic attacks.
The recommended dose is 2 inhalations 2-4 times a day. After achieving control over symptoms, the frequency of use is gradually reduced to maintenance - 2 times a day. To prevent asthma from physical exertion or before contact with suspected allergens, you can take an additional 2 inhalations immediately before physical activity.
The maximum daily dose is 8 inhalations.
As a rule, the effect of therapy is observed by the end of the first week of using the drug.
When used in combination with a bronchodilator, it is recommended to use it before Tailed Minta.
After adding the drug to glucocorticosteroids, a gradual reduction in their dose and even discontinuation is possible. During steroid dose reduction, careful monitoring of the patient's condition is required. The recommended dose reduction rate is 10% once a week. If it is impossible to reduce the dose of glucocorticosteroids, Tailed Mint should not be discontinued until the dose is restored to the original one.
Before first use, you need to shake the inhaler and press the metering valve 4 times (idle). If the inhaler has not been used for 7 days or longer, it is brought into working condition by pressing the valve 2 times.
Shake the inhaler vigorously before use. It should be held vertically. After exhaling as completely as possible, you need to insert the mouthpiece, without biting, between your teeth and wrap your lips tightly around it. I inhale through my mouth while simultaneously pressing the base of the can to spray a dose of the drug. You should hold your breath as long as possible and remove the inhaler from your mouth.
It is recommended to rinse and thoroughly dry the inhaler body at least once every 3 days.
Tilade® Mint
The drug is intended for regular daily use.
The drug is not intended for the relief of acute bronchospastic attacks.
Adults (including the elderly) and children over 2 years of age
The recommended dose of Tayled® Mint is 2 inhalations 2-4 times a day. Once symptom control is achieved, the dose is gradually reduced to a maintenance dose. The usual maintenance dose of the drug is 2 inhalations 2 times a day.
In severe cases, as well as with a high concentration of allergens, the dose of the drug can be increased to two inhalations 4 times a day.
The drug Tiled® Mint in the form of two inhalations (4 mg) once, carried out a few minutes before exposure to factors provoking the development of bronchospasm, can provide protection for several hours from the development of bronchospasm caused by physical activity (in case of physical exertion asthma), cold air, as well as inhaled allergens, atmospheric pollutants and other irritants.
The daily dose of the drug should not exceed 8 inhalations. The therapeutic effect develops by the end of the first week.
Concurrent bronchodilator therapy
If a bronchodilator is used simultaneously, it is recommended to use it before using Tailed® Mint.
Concomitant therapy with corticosteroids
The addition of Tailed® Mint to the treatment of patients receiving glucocorticosteroids may allow the maintenance dose of glucocorticosteroids to be reduced or discontinued completely. When reducing the dose of glucocorticosteroids, strict monitoring of the patient is necessary; A weekly dose reduction of 10% is suggested. If reducing the dose of glucocorticosteroids is impossible, then Tailed® Mint should not be discontinued until the “cover” of glucocorticosteroids is restored.
Using an inhaler
When using for the first time, shake the inhaler and press the metering valve 4 times (idle). If the inhaler has not been used for 3 days or more, it is necessary to return it to working condition by pressing the metering valve twice (idle).
When inhaling, follow the instructions below.
Remove the dust cap. Inspect the inside and outside of the plastic casing of the inhaler to make sure they are clean. Shake the inhaler vigorously.
Hold the inhaler upright with your thumb on the base of the canister. Exhale as completely as possible, then insert the mouthpiece into your mouth between your teeth (without biting it) and close your lips tightly.
Starting to inhale air through your mouth, press on the base of the canister so as to spray a dose of Tailed® Mint; At the same time, continue to breathe calmly and deeply.
Hold your breath and remove the inhaler from your mouth. Continue holding your breath for as long as possible.
The plastic body of the inhaler should be washed and thoroughly dried at least once every three days (see instructions for cleaning the inhaler).
After inhalation, always close the mouthpiece with a dust cap.
Children and patients who have difficulty coordinating pressing the dispensing device and inhaling may benefit from using an aerosol holding chamber to facilitate administration of the drug.
Standard mouthpiece (not synchronizer), suitable for use with a large number of aerosol holding chambers.
Instructions for cleaning your inhaler
It is important to keep the plastic mouthpiece clean to prevent excess medication from sticking, which will then be difficult to remove and may block the inhaler.
The plastic mouthpiece should be cleaned regularly and left to dry overnight every three days from the start of using the inhaler.
Standard inhaler
Cleaning the Mouthpiece
1. Remove the plastic dust cap and remove the metal cartridge from the mouthpiece before cleaning it.
2. Rinse the plastic mouthpiece through the top for 1 minute with hot tap water (approximately 45°C).
3. Rinse the other side of the plastic mouthpiece for one minute with hot tap water (approximately 45°C).
4. Shake off any remaining water from the inside of the mouthpiece by touching the mouthpiece to a hard surface on the side where it attaches to the outlet of the metal can.
5.Leave the plastic can to dry overnight.
6.Make sure the plastic mouthpiece is completely dry before attaching it to the metal canister and that the white rubber cover is pressed firmly against the metal canister.
IMPORTANT: If the inhaler becomes clogged, remove the plastic dust cap, disconnect (as in step 1) and soak the plastic mouthpiece in hot water for 20 minutes. Then repeat steps 2-6. Always make sure the mouthpiece is completely dry.
Never try to unlock the mouthpiece with a needle or sharp object. This will damage the inhaler. Do not place the metal can into water.
Do not remove the white rubber coating from the metal can.
Inhaler with synchronizer
Cleaning the Mouthpiece
1. Remove the plastic dust cap and remove the metal cartridge from the mouthpiece before cleaning it.
2. Rinse the plastic mouthpiece body through the top for 1 minute with hot tap water (approximately 45°C).
3. Rinse the other side of the plastic mouthpiece for one minute with hot tap water (approximately 45°C).
4. Shake off any remaining water from the inside of the mouthpiece by touching the mouthpiece to a hard surface on the side where it attaches to the outlet of the metal can.
5. Leave the plastic can to dry overnight.
IMPORTANT: If the inhaler becomes clogged, remove the plastic dust cap and disconnect (as in step 1) and soak the plastic mouthpiece in hot water for 20 minutes. Then repeat steps 2-5. Always make sure the mouthpiece is completely dry. Never try to unlock the mouthpiece with a needle or sharp object. This will damage the inhaler. Do not place the metal can into water.
special instructions
Tailed Mint should be used daily even in the absence of symptoms. Please note that relief may not occur immediately; it may take several weeks to achieve the effect.
Immediately after inhalation, bronchospasm may unexpectedly develop. This requires immediate treatment with short-acting inhaled bronchodilators, after which you need to seek emergency medical help. The use of Tailed Mint is immediately interrupted and alternative treatment is started.
For recurring bronchospasms, a bronchodilator is first inhaled, and immediately after inhalation the cough is calmed by drinking water.
Cancellation of Tailed Mint should be carried out gradually, over 7 days. It must be taken into account that asthma attacks may recur.
Similar drugs:
- Dexamethasone Solution for intravenous and intramuscular administration
- Calcium gluconate Chewable tablets
- Pulmicort Suspension for inhalation
- Cetrine Oral tablets
- Sodium cromoglicate Substance-powder
- Diprospan Solution for injection
- Mometasone furoate Substance-powder
- L-cet Oral tablets
- Dexamethasone Solution for injection
- Adrenaline (Adrenaline) Solution for injection
** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use Tailed Mint, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.
Are you interested in Tailed Mint? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.
** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Tailed Mint is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!
If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.
Aerosol for inhalation Tilade
Instructions for medical use of the drug
Description of pharmacological action
Stabilizes the membrane of mast cells and reduces the release of histamine, leukotriene C4, PG D2 and other biologically active substances from them.
Indications for use
Diseases of the respiratory tract with reversible obstruction: bronchial asthma of various origins, asthmatic bronchitis, exercise asthma, bronchospastic reactions caused by a number of stimuli, such as cold air, inhaled allergens, atmospheric pollution.
Release form
aerosol for inhalation dosed 2 mg/dose; bottle (bottle), box (box) 1; aerosol for inhalation dosed 2 mg/dose; bottle (bottle), box (box) 1;
Pharmacodynamics
Blocks the release of inflammatory mediators from various cells (eosinophils, mast cells, neutrophils, macrophages, monocytes and platelets), incl. histamine, cytokines, leukotriene C4, PGD2, chemotactic factors, enzymes (beta-glucuronidase, etc.). After inhalation, it settles on the walls of the bronchial tree and inhibits the development of the early and late stages of the asthmatic reaction caused by inhalation of the allergen. Reduces increased vascular permeability and has a local anti-inflammatory effect on the bronchial mucosa. Affects the endings of afferent nerves in the lungs, suppresses the axon reflex and promotes the release of sensory neuropeptides (substance P, neurotoxin A, etc.). Continuous long-term use reduces the hyperreactivity of the respiratory tract to nonspecific bronchoconstrictors, improves external respiration, reduces the intensity and frequency of asthma attacks and the severity of cough. Effective for mild and moderate forms of asthma. Improves nocturnal symptoms and reduces the need for daytime bronchodilator medications. When administered 30 minutes before exposure to a chemical irritant, allergen or physical activity, it prevents the development of an acute asthmatic reaction and suppresses its late phase, observed 6–12 hours after provocation. The therapeutic effect develops by the end of the first week; maximum improvement in clinical condition and lung function is usually observed within 2–4 weeks after the start of treatment.
Pharmacokinetics
After inhalation it settles on the walls of the bronchial tree. 5% of the administered dose enters the systemic circulation. A small amount (2–3%) is subsequently absorbed from the gastrointestinal tract. Plasma protein binding - up to 89%. Not metabolized, excreted unchanged from the body in urine (about 70%) and feces (about 30%).
Use during pregnancy
Prescribe with caution in the first trimester of pregnancy.
Contraindications for use
Hypersensitivity, age (up to 12 years).
Side effects
Headache, cough, bronchospasm, nausea, vomiting, abdominal pain, other dyspeptic disorders.
Directions for use and doses
Inhalation. For adults (including elderly people) and children over 12 years of age, the initial dose is 2 inhalations (4 mg) 4 times a day. If necessary, the dose of the drug can be increased to 2 inhalations 6–8 times a day. An additional dose can be taken immediately before physical activity to prevent physical asthma. Once adequate control of the symptoms of the disease is achieved, a transition to maintenance therapy of 2 inhalations 2 times a day is possible. The therapeutic effect develops by the end of the first week of taking the drug.
Overdose
The likelihood of an overdose is extremely low. If it develops, symptomatic treatment is carried out.
Interactions with other drugs
Compatible with oral and inhaled forms of beta-adrenergic receptor stimulants and corticosteroids, theophylline and other methylxanthine derivatives, as well as ipratropium bromide (with all such combinations a potentiation effect is possible).
Precautions for use
Regular daily intake is required. Do not use to relieve an acute attack of suffocation.
Storage conditions
List B.: In a place protected from light, at a temperature not exceeding 30 °C (do not freeze).
Best before date
36 months
ATX classification:
R Respiratory system
R03 Drugs for the treatment of bronchial asthma
R03B Other drugs for inhalation use for the treatment of bronchial asthma
R03BC Antiallergic drugs (excluding glucocorticoids)
R03BC03 Nedocromil
